Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Several MCU heroes and villains' superpowers and enhanced abilities are an original addition exclusive to the Marvel ...

The flagship version of the new crossover should pack the same 510 hp as the Model 3 Performance. Tesla has equipped this ...

With the new year already here, Samsung is gearing up to expand its Galaxy lineup with fresh smartphones. Not only is the ...

Samsung's highly anticipated Galaxy S25 Slim seems to have been benchmarked for the very first time with a Snapdragon 8 Elite ...

Across China’s west, the Communist Party is placing children in boarding schools to assimilate a generation of Tibetans into the national mainstream and mold them into loyal citizens. By Chris ...

Christopher Mims is a columnist who writes about technology for The Wall Street Journal's tech bureau in San Francisco. The subjects of his columns vary widely from one week to the next.

In developed markets, especially those of Japan, USA and EU, medical organizations and practitioners are reputed for being conservative, and changing suppliers or adopting new technologies for medical ...